article thumbnail

MHRA warns of serious eye-related adverse events after Dupixent use

Pharmaceutical Technology

GlobalData anticipates that this safety update will likely raise physician and regulator vigilance regarding long-term Dupixent use but is unlikely to impact overall prescribing patterns for the product. This will, however, likely trigger Dupixent’s competitors to look more closely at the safety of their products.

article thumbnail

Revolutionizing Pharmacovigilance with Proactive Signal Detection

PM360

Up to now, drug safety teams have relied primarily on reactive reporting systems for pharmacovigilance (PV) or real-world drug safety monitoring. Most traditional signal detection methods focus on disproportionality, meanwhile calling attention to higher-than-expected correlations between the suspect drug and an adverse event (AE).

Safety 106
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

ESMO 2022: Ten key takeaways on Europe’s top oncology event

Clarivate

As part of the Drugs to Watch program, Clarivate experts use proprietary data sources, landscape and event monitoring and deep market knowledge to identify key drug developments expected to have a significant impact on patients and markets. 8] Median PFS (secondary endpoint) also significantly improved with fruquintinib versus control (3.7

article thumbnail

AstraZeneca BTK inhibitor tablet approved in EU for leukaemia

European Pharmaceutical Review

Today’s approval offers physicians and patients in the EU more flexibility to determine the right treatment plan and enables more patients to potentially benefit from this medicine,” explained Dave Fredrickson, Executive Vice President of AstraZeneca’s Oncology Business Unit.

Safety 82
article thumbnail

AbbVie’s Skyrizi® shows long-term efficacy in psoriatic arthritis

European Pharmaceutical Review

The long-term data analyses of the Phase III KEEPsAKE 1 and 2 trials also revealed no new observed safety signals through 100 weeks. ” Skyrizi was generally well-tolerated and no new safety signals were noted in both KEEPsAKE 1 and 2 at 100 weeks of treatment. . Serious treatment-emergent adverse events (TEAEs) occurred at 7.6

Safety 68
article thumbnail

Using data analytics to better manage care transitions

Clarify Health

Customizing programs for patient safety and care quality: Poorly managed care transitions can lead to medical errors, medication discrepancies, and other safety concerns. By actively managing transitions, hospitals can reduce the likelihood of adverse events, improve patient safety, and enhance overall healthcare quality.

article thumbnail

X4 Pharmaceuticals announces positive top-line results for WHIM Syndrome drug

pharmaphorum

In a global, randomised, double-blind, placebo-controlled, multicentre study, researchers evaluated the safety and efficacy of mavorixafor in people with genetically confirmed WHIM syndrome. The drug was generally well tolerated by patients, with no treatment-related serious adverse events reported and no discontinuations for safety events.